|
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
SINGAPORE, Nov 01, 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
3F Mosquito, a fragrance made up of specialized oils sourced from botanicals that mosquitoes avoid, has shown 100% repellency against mosquitoes in laboratory testing. Global BioLife contracted U.S-based Snell Scientifics LLC ("Snell") in Meansville, Georgia to conduct the mosquito studies for the mosquito deterring technologies.
In August 2017 SeD announced that Global BioLife was collaborating with U.S-based Chemia Corporation to develop a suite of fragrances for medical applications referred to as 3F (Functional Fragrance Formulation). Global BioLife entered into further collaboration with Chemia to co-develop 3F Mosquito for laundry detergents, shampoos and lotions.
3F Mosquito products are based on extensive research of botanical oils which possess mosquito repelling properties. When 3F is infused into products such as detergents, shampoos, and lotions, consumers will be provided with multiple layers of protection against mosquito bites, a revolutionary alternative to traditional mosquito repellents.
"Chemia is very excited to introduce these sustainable and tested fragrances to provide natural alternatives to protecting consumers from the risk of mosquito transmitted diseases," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
The uniquely-designed mosquito deterring paints and functional fabric both deter mosquitoes by chemical-free photonic means; a wavelength of light is emitted that mosquitoes avoid. Snell reported that Global BioLife's photonic mosquito paints and mosquito fabric both exhibit degrees of repellency effective against mosquitoes.
Global BioLife and Chemia have designed the mosquito deterring fabric for use in outdoor apparel, hats, tents, and other camping gear. The mosquito deterring paints were designed as exterior paints for homes as well as commercial applications. These new mosquito deterring technologies are non-chemical methods of repelling mosquitoes for consumers. Mr. Daryl Thompson, Global BioLife Director of Scientific Initiatives, said "The objective in the design of 3F Mosquito was to identify and create a suitable formula that was both pleasant and would excel in protective abilities against mosquitoes. These oils are scientifically proven to affect mosquitoes' receptors, essentially making the mosquito blind to your presence. 3F offers a pleasant scent while providing layers of protection to keep people safe from mosquito bites."
The market for safe mosquito repellents and deterrents is growing as the risk of Zika grows. The most vulnerable group of our population at highest risk for Zika infection may be pregnant women, because of their avoidance and dislike of products containing Deet. The US Center for Disease Control has released multiple statements that the use of Deet is safe, however pregnant women continue to be hesitant to use Deet-containing products.
Dr. Peggy Tang, Global BioLife's CEO, commented: "We expect that these new techniques for fighting mosquito bites will be very appealing to consumers. We are providing unique and useful products, free of harsh chemicals. Due to the perceived toxicity of Deet and the avoidance of chemicals by consumers, Global BioLife's chemical-free products will have a direct advantage over traditional mosquito repellents."
"Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This collaboration marks one of the first steps in actively changing the game of healthcare," said SeD and Global BioLife Executive Chairman Mr. Chan Heng Fai.
Mr. Thomas Meyer added: "This groundbreaking partnership with Global BioLife sets the stage for a steady stream of innovative fragrances that feature functional properties in various consumer product applications."
In addition to 3F Mosquito, Global BioLife is working with Chemia on the formulation of additional 3F fragrances to fight stress and anxiety and 3F for anti-viral medical applications.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") and Australian Exchange-listed Holista CollTech Limited ("Holista") in equal proportions of 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com About Chemia Corporation
Chemia Fragrance and Flavor provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. For more information, please visit: http://www.chemiacorp.com.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals Dec 15, 2025 23:00 JST
|  NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport Dec 15, 2025 19:41 JST
|  NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz Dec 15, 2025 19:04 JST
|  Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership Dec 15, 2025 08:30 JST
|  HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion Dec 12, 2025 23:15 JST
|  Honda to Launch New Heritage Service Business
Dec 12, 2025 20:31 JST
|  Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz Dec 12, 2025 19:59 JST
|  NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries Dec 12, 2025 18:13 JST
|  Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition Dec 12, 2025 11:00 JST
|  Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year Dec 11, 2025 19:41 JST
|  NEC Named to CDP's "A List" for Climate Change and Water Security for the Seventh Consecutive Year Dec 11, 2025 19:00 JST
|  MHI Successfully Produces Hydrogen at Its Ammonia Cracking Pilot Plant Using Steam Heating Dec 10, 2025 18:14 JST
|  NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025 Dec 10, 2025 12:00 JST
|  "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List Dec 09, 2025 18:51 JST
|  NEC Wins TIP MUST Silver Badge with Advanced Network Operating System for Open Optical Transponders Dec 09, 2025 13:39 JST
|  MHI and Worley to Deliver Full-Scale Carbon Capture Facility for Heidelberg Materials UK's Padeswood Cement Works Dec 08, 2025 17:00 JST
|  Honda Technical Support for Red Bull Powertrains in F1 Racing Concludes Dec 08, 2025 16:34 JST
|  MHIET U.S. Subsidiary's Franklin Plant Celebrates 10th Anniversary Dec 08, 2025 16:03 JST
|  Lexus World Premieres Lexus LFA Concept BEV Sports Car Dec 05, 2025 19:13 JST
|  TOYOTA GAZOO Racing World Premieres GR GT & GR GT3 Dec 05, 2025 18:58 JST
|
More Latest Release >>
|